Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Conditions:   Thyroid Cancer;   Thyroid Cancer, Follicular;   Papillary Thyroid Cancer;   Follicular Thyroid Cancer;   Hurthle Cell Tumor;   Poorly Differentiated Thyroid Gland Carcinoma;   Hurthle Cell Thyroid Neoplasia
Interventions:   Drug: Trametinib;   Drug: Dabrafenib;   Drug: PDR001
Sponsor:   Memorial Sloan Kettering Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 11, 2020 / by / in
Comments